OCT - RNFL on 19-06-2017 5. Other adverse drug reactions (reported in 1 to 4% of patients) with The following adverse reactions have been identified during postapproval use of There are no adequate and well-controlled studies of In embryofetal developmental studies, administraton of bimatoprost to pregnant mice and rats during organogenesis, resulted in abortion and early delivery at oral doses at least 33 times (mice) or 94 times (rats) the human exposure to bimatoprost 0.03% dosed bilaterally once daily (based on blood area under the curve [AUC] levels). Approximately 12% of bimatoprost remains unbound in human plasma.Metabolism: Bimatoprost is the major circulating species in the blood once it reaches the systemic circulation following ocular dosing.

These effects were observed at exposures at least 41 times the human systemic exposure to bimatoprost 0.03% dosed bilaterally once daily, based on AUC. Lumigan may also be used for purposes not listed in this medication guide. The most frequently reported changes have been increased pigmentation of the iris, periorbital tissue (eyelid) and eyelashes.

This medicine may be used on its own or with other drops called beta-blockers which also reduce pressure. There was noDistribution: Bimatoprost is moderately distributed into body tissues with a steady-state volume of distribution of 0.67 L/kg. The manufacturer of bimatoprost (Lumigan ®) has discontinued the 0.3mg/ml or 0.03% strength of this product in dropped bottles, the 0.01% product and the unit dose version are not affected and remain available..

//ajax success content here. Lumigan (bimatoprost ophthalmic solution) is a synthetic prostamide analog with ocular hypotensive activity that works by regulating the flow of fluid within the eye to maintain a normal pressure used to treat certain types of glaucoma and other causes of high pressure inside the eye. There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. Bimatoprost then undergoes oxidation, N-deethylation and glucuronidation to form a diverse variety of metabolites.Elimination: Following an intravenous dose of radiolabeled bimatoprost (3.12 mcg/kg) to six healthy subjects, the maximum blood concentration of unchanged drug was 12.2 ng/mL and decreased rapidly with an elimination half-life of approximately 45 minutes. Bimatoprost is believed to lower intraocular pressure (IOP) in humans by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes. Do not use Lumigan eye drops while wearing contact lenses. Up to 67% of the administered dose was excreted in the urine while 25% of the dose was recovered in the feces.Bimatoprost was not carcinogenic in either mice or rats when administered by oral gavage for 104 weeks at doses up to 2 mg/kg/day and 1 mg/kg/day, respectively (192 and 291 times the estimated human systemic exposure to bimatoprost 0.03% dosed bilaterally once daily, respectively, based on blood AUC levels)Bimatoprost was not mutagenic or clastogenic in the Ames test, in the mouse lymphoma test, or in the Bimatoprost did not impair fertility in male or female rats up to doses of 0.6 mg/kg/day (at least 103 times the recommended human exposure to bimatoprost 0.03% dosed bilaterally once daily based on blood AUC levels).In a 12-month clinical study of patients with open angle glaucoma or ocular hypertension with an average baseline IOP of 23.5 mmHg, the IOP-lowering effect of polyethylene ophthalmic dispenser bottles and tips with turquoise polystyrene caps in the following sizes:Advise patients about the potential for increased brown pigmentation of the iris, which may be permanent. The recommended dosage is one drop in the affected eye(s) once daily in the evening.